Oragenics Inc. (NYSEMKT:OGEN) a leader in the development of novel effective antibiotics and oral care probiotics announced that Mr. Al Fosmoe has joined Oragenics as Senior Vice President Operations/Product Development. The appointment is directly related to the progress Oragenics has made in the development of a new pipeline of novel antibiotics from its lantibiotic platform and marks the expansion of the team dedicated to accelerating the progress of the lantibiotic pipeline. Oragenics Inc (NYSEMKT:OGEN) shares after opening at $2.27 moved to $2.28 on last trade day and at the end of the day closed at $2.10 . Company price to sales ratio in past twelve months was calculated as 2.10 and price to cash ratio as 4.66. Oragenics Inc (NYSEMKT:OGEN) showed a negative weekly performance of -11.39%.
Biota Pharmaceuticals, Inc (NASDAQ:BOTA) announced its financial results for the three month and six month periods ended December 31, 2013, and provided an update on recent corporate developments. Biota Pharmaceuticals Inc (NASDAQ:BOTA) shares fell -7.50% in last trading session and ended the day on $5.43. BOTA return on equity ratio is recorded as -14.90% and its return on assets is -12.10 %. Biota Pharmaceuticals Inc (NASDAQ:BOTA) yearly performance is 30.84%.
Citigroup Inc. initiated coverage on shares of Puma Biotechnology Inc (NASDAQ:PBYI) in a research note released on Monday morning,TheFlyOnTheWall.com reports. The firm issued a buy rating and a $123.00 target price on the stock. Puma Biotechnology Inc (NYSE:PBYI) shares moved down -7.85% in last trading session and was closed at $71.30 while trading in range of $70.67 – $76.13 – Puma Biotechnology Inc (NYSE:PBYI) year to date (YTD) performance is -31.13%.
Insys Therapeutics, Inc. (NASDAQ:INSY) announced that the Company will present at the 39th Annual Deutsche Bank Health Care Conference on May 7 – 8, 2014 at the InterContinental Hotel in Boston, MA.Insys Therapeutics Inc (NASDAQ:INSY) weekly performance is 1.53%. On last trading day company shares ended up $39.23. Insys Therapeutics Inc (NASDAQ:INSY) distance from 50-day simple moving average (SMA50) is -8.37%. Analysts mean target price for the company is $62.00.